Clinical Trial Update: Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) [Phase 2]

View source ↗

Summary

Phase 2 study update for ALN-RSV01 in lung transplant patients with RSV infection completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Transplant Complications
• Respiratory Syncytial Virus Infections

Drugs mentioned

• ALN-RSV01

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED